Bio-Gene Technology Limited (BGT.AX)
AUD 0.04
(0.0%)
AUD 0.04
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 368.44 Thousand AUD | -39.98% |
| 2023 | 613.88 Thousand AUD | -40.67% |
| 2022 | 1.03 Million AUD | 37.12% |
| 2021 | 754.57 Thousand AUD | 33.01% |
| 2020 | 567.28 Thousand AUD | -7.55% |
| 2019 | 613.61 Thousand AUD | -19.22% |
| 2018 | 759.58 Thousand AUD | 103.13% |
| 2017 | 373.93 Thousand AUD | -2.37% |
| 2016 | 383 Thousand AUD | 0.0% |
| 2015 | - AUD | -100.0% |
| 2014 | 955.00 AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 368.44 Thousand AUD | 0.0% |
| 2024 Q2 | 601.58 Thousand AUD | 0.0% |
| 2024 FY | 368.44 Thousand AUD | -39.98% |
| 2023 Q2 | 935.26 Thousand AUD | 0.0% |
| 2023 Q4 | 613.88 Thousand AUD | 0.0% |
| 2023 FY | 613.88 Thousand AUD | -40.67% |
| 2022 Q4 | 1.03 Million AUD | 0.0% |
| 2022 FY | 1.03 Million AUD | 37.12% |
| 2022 Q2 | 864.46 Thousand AUD | 0.0% |
| 2021 Q2 | 774.32 Thousand AUD | 0.0% |
| 2021 FY | 754.57 Thousand AUD | 33.01% |
| 2021 Q4 | 754.57 Thousand AUD | 0.0% |
| 2020 Q4 | 567.28 Thousand AUD | 0.0% |
| 2020 FY | 567.28 Thousand AUD | -7.55% |
| 2020 Q2 | 654.68 Thousand AUD | 0.0% |
| 2019 FY | 613.61 Thousand AUD | -19.22% |
| 2019 Q4 | 613.61 Thousand AUD | 0.0% |
| 2019 Q2 | 522.18 Thousand AUD | 0.0% |
| 2018 Q2 | 250.73 Thousand AUD | 0.0% |
| 2018 FY | 759.58 Thousand AUD | 103.13% |
| 2018 Q4 | 759.58 Thousand AUD | 0.0% |
| 2017 Q4 | 449.93 Thousand AUD | 0.0% |
| 2017 FY | 373.93 Thousand AUD | -2.37% |
| 2016 FY | 383 Thousand AUD | 0.0% |
| 2015 FY | - AUD | -100.0% |
| 2014 FY | 955.00 AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 91.288% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -20.074% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 96.062% |
| Biome Australia Limited | 5.37 Million AUD | 93.143% |
| Patrys Limited | 691.36 Thousand AUD | 46.707% |
| Orthocell Limited | 22.08 Million AUD | 98.332% |
| Imugene Limited | 33.14 Million AUD | 98.888% |
| Noxopharm Limited | 1.28 Million AUD | 71.408% |
| PYC Therapeutics Limited | 10.18 Million AUD | 96.382% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 97.122% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 84.157% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 77.339% |
| Cynata Therapeutics Limited | 1.17 Million AUD | 68.537% |
| CSL Limited | 27.88 Billion AUD | 99.999% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 82.085% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 98.689% |
| Starpharma Holdings Limited | 8.69 Million AUD | 95.764% |
| Nanollose Limited | 465.64 Thousand AUD | 20.874% |
| Memphasys Limited | 5.59 Million AUD | 93.412% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | 14.638% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -330.011% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 89.248% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 90.128% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | 64.763% |
| Race Oncology Limited | 1.91 Million AUD | 80.774% |
| Nyrada Inc. | 855.63 Thousand AUD | 56.939% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.852% |
| Dimerix Limited | 13.89 Million AUD | 97.348% |
| PharmAust Limited | 896.6 Thousand AUD | 58.907% |
| Immutep Limited | 10.97 Million AUD | 96.644% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 95.578% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 93.209% |
| BTC Health Limited | 203.94 Thousand AUD | -80.657% |
| Acrux Limited | 5.68 Million AUD | 93.521% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 99.138% |
| Biotron Limited | 737.5 Thousand AUD | 50.042% |
| Tissue Repair Ltd | 1.35 Million AUD | 72.726% |
| AdAlta Limited | 3.54 Million AUD | 89.599% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 99.175% |
| Hexima Limited | 248.67 Thousand AUD | -48.167% |
| AnteoTech Limited | 4.07 Million AUD | 90.959% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 89.721% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 97.682% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | 60.868% |
| Actinogen Medical Limited | 1.61 Million AUD | 77.191% |
| Immuron Limited | 2.84 Million AUD | 87.029% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 84.817% |